Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro
| dc.contributor.author | Żołnierczyk, Jolanta | |
| dc.contributor.author | Kaźmierczuk, Arleta | |
| dc.contributor.author | Hikisz, Paweł | |
| dc.contributor.author | Cebula-Obrzut, Barbara | |
| dc.contributor.author | Wawrzyniak, Ewa | |
| dc.contributor.author | Błoński, Jerzy Z. | |
| dc.contributor.author | Misiewicz, Małgorzata | |
| dc.contributor.author | Robak, Paweł | |
| dc.contributor.author | Smolewski, Piotr | |
| dc.contributor.author | Kiliańska, Zofia M. | |
| dc.date.accessioned | 2015-06-12T07:08:41Z | |
| dc.date.available | 2015-06-12T07:08:41Z | |
| dc.date.issued | 2015-03-05 | |
| dc.identifier.issn | 2090-9071 | |
| dc.identifier.uri | http://hdl.handle.net/11089/9501 | |
| dc.description.abstract | It has been previously revealed that statins used at high concentrations display antileukemic potential towards chronic lymphocytic leukemia (CLL) cells. However, their usage alone in clinical practice may be limited due to possible side effects of high doses of these drugs. On the other hand, combined treatment of leukemia with statins and the conventional chemotherapeutics is questionable because of unknown influence of the first on the standard treatment results. This study has revealed that in vitro atorvastatin increases the proapoptotic potential of cladribine and mafosfamide in CLL cells isolated from peripheral blood of patients. Moreover, a preincubation with the above statin sensitizes leukemic cells to CM-induced apoptosis even at small concentrations of the drug. The usage of atorvastatin together with or followed by the conventional chemotherapy should be considered as therapeutic option for the treatment for this leukemia. Interestingly, CM-resistant patients might have the biggest benefits from atorvastatin administration. | pl_PL |
| dc.description.sponsorship | Grant no. 1407 from the University of Łódź. | pl_PL |
| dc.language.iso | en | pl_PL |
| dc.publisher | Hindawi Publishing Corporation | pl_PL |
| dc.relation.ispartofseries | Journal of Chemistry;Volume 2015 (2015) | |
| dc.rights | Uznanie autorstwa 3.0 Polska | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
| dc.title | Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro | pl_PL |
| dc.type | Article | pl_PL |
| dc.page.number | 1-11 | pl_PL |
| dc.contributor.authorAffiliation | Żołnierczyk Jolanta D., University of Łódź, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection | pl_PL |
| dc.contributor.authorAffiliation | Kaźmierczuk, Arleta, University of Łódź, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection | pl_PL |
| dc.contributor.authorAffiliation | Hikisz Paweł, University of Łódź, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection | pl_PL |
| dc.contributor.authorAffiliation | Cebula-Obrzut Barbara, Medical University of Łódź, Department of Experimental Hematology, | pl_PL |
| dc.contributor.authorAffiliation | Wawrzyniak Ewa, Medical University of Łódź, Department of Hematology, | pl_PL |
| dc.contributor.authorAffiliation | Błoński Jerzy Z., Medical University of Łódź, Department of Hematology, | pl_PL |
| dc.contributor.authorAffiliation | Misiewicz Małgorzata , Medical University of Łódź, Department of Hematology, | pl_PL |
| dc.contributor.authorAffiliation | Robak Paweł, Medical University of Łódź, Department of Experimental Hematology | pl_PL |
| dc.contributor.authorAffiliation | Smolewski Piotr, Medical University of Łódź, Department of Experimental Hematology | pl_PL |
| dc.contributor.authorAffiliation | Kiliańska, Zofia M., University of Łódź, Department of Cytobiochemistry, Faculty of Biology and Environmental Protection | pl_PL |
| dc.references | G. Gaidano, R. Foa, and R. Dalla-Favera, “Molecular pathogenesis of chronic lymphocytic leukemia,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3432–3438, 2012. | pl_PL |
| dc.references | P. Smolewski, M. Witkowska, andA. Korycka-Wołowiec, “New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia,” ISRN Oncology, vol. 2013, Article ID 740615, 7 pages, 2013. | pl_PL |
| dc.references | M. Wu, A. Akinleye, and X. Zhu, “Novel agents for chronic lymphocytic leukemia,” Journal of Hematology and Oncology, vol. 6, no. 1, article 36, 2013. | pl_PL |
| dc.references | A. Cuneo, F. Cavazzini,M. Ciccone et al., “Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups,” CancerMedicine, vol. 3, no. 3, pp. 555– 564, 2014. | pl_PL |
| dc.references | L. Amrein, M. Shawi, J. Grenier, R. Aloyz, and L. Panasci, “The phosphatidylinositol-3 kinase i inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro,” International Journal of Cancer, vol. 133, no. 1, pp. 247–252, 2013. | pl_PL |
| dc.references | J. C. Gea-Banacloche, “Rituximab-associated infections,” Seminars in Hematology, vol. 47, no. 2, pp. 187–198, 2010. | pl_PL |
| dc.references | A. R. Tonelli, R. Lottenberg, R. W. Allan, and P. S. Sriram, “Rituximab-induced hypersensitivity pneumonitis,” Respiration, vol. 78, no. 2, pp. 225–229, 2009. | pl_PL |
| dc.references | M. L. Hartman and Z. M. Kilianska, “Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia,” Contemporary Oncology, vol. 16, no. 6, pp. 474–479, 2012. | pl_PL |
| dc.references | D. E. Spaner, E. Lee, Y. Shi et al., “PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia,” Leukemia, vol. 27, no. 5, pp. 1090–1099, 2013. | pl_PL |
| dc.references | M. F. Mulas, C. Abete, D. Pulisci et al., “Cholesterol esters as growth regulators of lymphocytic leukaemia cells,” Cell Proliferation, vol. 44, no. 4, pp. 360–371, 2011. | pl_PL |
| dc.references | T. P. Ahern, T. L. Lash, P. Damkier, P.M. Christiansen, and D. P. Cronin-Fenton, “Statins and breast cancer prognosis: evidence and opportunities,” The Lancet Oncology, vol. 15, no. 10, pp. e461–e468, 2014. | pl_PL |
| dc.references | P. Jiang, R. Mukthavaram, Y. Chao et al., “In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells,” British Journal of Cancer, vol. 111, no. 8, pp. 1562–1571, 2014. | pl_PL |
| dc.references | A. Sławi´nska-Brych, B. Zdzisi´nska, and M. Kandefer-Szersze´n, “Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line,” Pharmacological Reports, vol. 66, no. 1, pp. 121–129, 2014. | pl_PL |
| dc.references | W. A. Maltese and J. R. Aprille, “Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells,”The Journal of Biological Chemistry, vol. 260, no. 21, pp. 11524–11529, 1985. | pl_PL |
| dc.references | I.-M.Astrand, E. Fries,T.Chojnacki, andG.Dallner, “Inhibition of dolichyl phosphate biosynthesis by compactin in cultured rat hepatocytes,” European Journal of Biochemistry, vol. 155, no. 2, pp. 447–452, 1986. | pl_PL |
| dc.references | A.W. Alberts, “Lovastatin and simvastatin—inhibitors ofHMG CoAreductase and cholesterol biosynthesis,” Cardiology, vol. 77, no. 4, pp. 14–21, 1990. | pl_PL |
| dc.references | N. Vallianou, A. Kostantinou, M. Kougias, and C. Kazazis, “Statins and Cancer,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 5, pp. 706–712, 2014. | pl_PL |
| dc.references | J. H. Jackson, C. G. Cochrane, J. R. Bourne, P. A. Solski, J. E. Buss, and C. J. Der, “Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 8, pp. 3042–3046, 1990. | pl_PL |
| dc.references | A. A. Al-Haidari, I. Syk, and H. Thorlacius, “HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation,” Biochemical and Biophysical Research Communications, vol. 446, no. 1,pp. 68–72, 2014. | pl_PL |
| dc.references | S. Ishikawa, H. Hayashi, K. Kinoshita et al., “Statins inhibit tumor progression via an enhancer of zeste homolog 2- mediated epigenetic alteration in colorectal cancer,” International Journal of Cancer, vol. 135, no. 11, pp. 2528–2536, 2014. | pl_PL |
| dc.references | M. Podhorecka,D.Halicka, P.Klimek, M.Kowal, S.Chocholska, and A. Dmoszynska, “Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells,” Annals of Hematology, vol. 89, no. 11, pp. 1115–1124, 2010. | pl_PL |
| dc.references | J. D. Zołnierczyk, A. Borowiak, P. Hikisz et al., “Promising antileukemic activity of atorvastatin,” Oncology Reports, vol. 29, no. 5, pp. 2065–2071, 2013. | pl_PL |
| dc.references | B.D. Cheson, J. M. Bennett, M. Grever et al., “National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996. | pl_PL |
| dc.references | A. Kobyli´nska, J. Bednarek, J. Z. Blonski et al., “In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone,” Oncology Reports, vol. 16, no. 6, pp. 1389–1395, 2006. | pl_PL |
| dc.references | O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. | pl_PL |
| dc.references | U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. | pl_PL |
| dc.references | H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic transfer of proteins frompolyacrylamide gels to nitrocellulose sheets: Procedure and some applications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 9, pp. 4350–4354, 1979. | pl_PL |
| dc.references | D. J.McConkey, “Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei,” The Journal of Biological Chemistry, vol. 271, no. 37, pp. 22398–22406, 1996. | pl_PL |
| dc.references | P. Garnier, W. Ying, and R. A. Swanson, “Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase-1,” Journal of Neuroscience, vol. 23, no. 22, pp. 7967–7973, 2003. | pl_PL |
| dc.references | P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris, “Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells,” Carcinogenesis, vol. 26, no. 5, pp. 883–891, 2005. | pl_PL |
| dc.references | I. Yavasoglu, G. Sargin, G.Kadikoylu, A.Karul, and Z. Bolaman, “The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro,” Medical Oncology, vol. 30, no. 3, article 603, 2013. | pl_PL |
| dc.references | S. Al-harbi, B. T. Hill, S. Mazumder et al., “An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737,” Blood, vol. 118, no. 13, pp. 3579–3590, 2011. | pl_PL |
| dc.references | A. Furlan, F. Villanova, F. Pietrogrande,M. Celadin, M. Sanzari, and F. Vianello, “Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro,” Leukemia & Lymphoma, vol. 51, no. 1, pp. 107–113, 2010. | pl_PL |
| dc.references | A. G. Bosanquet and P. B. Bell, “Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined disc assaymethodology,” Leukemia Research, vol. 20,no. 2, pp. 143–153, 1996. | pl_PL |
| dc.references | A. G. Bosanquet, S. M. Richards, R. Wade et al., “Drug crossresistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing,” British Journal of Haematology, vol. 146, no. 4, pp. 384–395, 2009. | pl_PL |
| dc.references | J. D. ˙Zołnierczyk, A. Borowiak, J. Z. Blonski et al., “In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent,” Pharmacological Reports, vol. 65, no. 2, pp. 460–475, 2013. | pl_PL |
| dc.references | X.-J. Yan, E. Albesiano, N. Zanesi et al., “B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatmentresistant human chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 31, pp. 11713–11718, 2006. | pl_PL |
| dc.references | U. Klein and R. Dalla-Favera, “New insights into the pathogenesis of chronic lymphocytic leukemia,” Seminars in Cancer Biology, vol. 20, no. 6, pp. 377–383, 2010. | pl_PL |
| dc.references | D. Bagnara, M. S. Kaufman, C. Calissano et al., “A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease,” Blood, vol. 117, no. 20, pp. 5463–5472, 2011. | pl_PL |
| dc.references | A. A. Filip, B. Ciseł, and E. Wąsik-Szczepanek, “Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes,” Clinical and Experimental Medicine, vol. 15, no. 1, pp. 73–83, 2015. | pl_PL |
| dc.references | E. Matutes, A. G. Bosanquet, R.Wade, S. M. Richards, M. Else, and D. Catovsky, “The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry,” Leukemia, vol. 27, no. 2, pp. 507–510, 2013. | pl_PL |
| dc.references | T. Robak and P. Robak, “Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias,” Current Pharmaceutical Design, vol. 18, no. 23, pp. 3373–3388, 2012. | pl_PL |
| dc.references | E. Rosati, R. Sabatini, G. Rampino et al., “Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL,” Blood, vol. 116, no. 15, pp. 2713–2723, 2010. | pl_PL |
| dc.references | X. Peng, W. Li, L. Yuan, R. G. Mehta, L. Kopelovich, and D. L. McCormick, “Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21,” PLoS ONE, vol. 8, no. 8,Article ID e70442, 2013. | pl_PL |
| dc.references | S. Ghavami, P. Sharma, B. Yeganeh et al., “Airwaymesenchymal cell death by mevalonate cascade inhibition: integration of autophagy, unfolded protein response and apoptosis focusing on Bcl2 family proteins,” Biochimica et Biophysica Acta, vol. 1843, no. 7, pp. 1259–1271, 2014. | pl_PL |
| dc.references | E. Głodkowska-Mrowka, P.Mrowka, G.W. Basak et al., “Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib,” Experimental Hematology, vol. 42, no. 6, pp. 439–447, 2014. | pl_PL |
| dc.references | M.Winiarska, J. Bil, E.Wilczek et al., “Statins impair antitumor effects of Rituximab by inducing conformational changes of CD20,” PLoS Medicine, vol. 5, no. 3, article e64, 2008. | pl_PL |
| dc.references | A. Poggi, S. Boero, A. Musso, and M. R. Zocchi, “Selective role ofmevalonate pathway in regulating perforin but not FasL and TNFalpha release in human natural killer cells,” PLoS ONE, vol. 8, no. 5, Article ID e62932, 2013. | pl_PL |
| dc.references | A. Novak, B. Binnington, B. Ngan, K. Chadwick, N. Fleshner, and C. A. Lingwood, “Cholesterol masksmembrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies,” Glycobiology, vol. 23, no. 11, pp. 1230–1239, 2013. | pl_PL |
| dc.references | S. Pisanti, P. Picardi, E. Ciaglia, A.D’Alessandro, and M. Bifulco, “Novel prospects of statins as therapeutic agents in cancer,” Pharmacological Research, vol. 88, pp. 84–98, 2014. | pl_PL |
| dc.references | Y. K. Chae, L. Trinh, P. Jain et al., “Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.,” Blood, vol. 123, no. 9, pp. 1424–1426, 2014. | pl_PL |
| dc.references | S. J. Lee, I. Lee, J. Lee, C. Park, and W. K. Kang, “Statins potentiate the anti-angiogenic effects of bevacizumab in human colorectal cancer,” The British Journal of Cancer, vol. 111, no. 3, pp. 497–505, 2014. | pl_PL |
| dc.references | S. Bonovas, “Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes?” Drugs, vol. 74, no. 16, pp. 1841–1848, 2014. | pl_PL |
| dc.references | M. F. Carrascosa, J. R. Salcines-Caviedes,M. I. Lucena, and R. J. Andrade, “Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?” Journal of Hepatology, vol. 62, no. 3, pp. 751–752, 2015. | pl_PL |
| dc.references | U. K. Sampson, M. F. Linton, and S. Fazio, “Are statins diabetogenic?” Current Opinion in Cardiology, vol. 26, no. 4, pp. 342– 347, 2011. | pl_PL |
| dc.contributor.authorEmail | zkilian@biol.uni.lodz.pl | pl_PL |
Pliki tej pozycji
Pozycja umieszczona jest w następujących kolekcjach
Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako Uznanie autorstwa 3.0 Polska